FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors
- 22 August 2003
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 16 (3) , 409-417
- https://doi.org/10.1016/s1521-6926(03)00063-x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemiaBlood, 2001
- Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemiaBlood, 2001
- FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk groupBritish Journal of Haematology, 2000
- Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual diseaseLeukemia, 2000
- Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemiaMedical and Pediatric Oncology, 1999
- Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in childrenBritish Journal of Haematology, 1999
- Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 geneBritish Journal of Haematology, 1999
- Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell linesLeukemia, 1997
- Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasiaLeukemia, 1997
- Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemiaLeukemia, 1997